Drug Profile
Research programme: beta-amyloid inhibitors - Alterity Therapeutics
Alternative Names: Aβ inhibitors - Alterity Therapeutics; Metallocomplex programme - Alterity Therapeutics; VK-11; VK-12Latest Information Update: 17 Apr 2019
Price :
$50
*
At a glance
- Originator Prana Biotechnology
- Developer Alterity Therapeutics
- Class Imaging agents; Organometallic compounds; Phenanthrolines; Platinum complexes
- Mechanism of Action Amyloid beta-protein inhibitors; Chelating agents; Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 08 Apr 2019 Prana Biotechnology is now called Alterity Therapeutics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Australia (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease(Diagnosis) in Australia (PO)